Stock Market Reviews

TRDA (Entrada Therapeutics, Inc.) News

Get the latest news, insights, and market updates on TRDA (Entrada Therapeutics, Inc.). Explore the news page 3 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• Entrada Therapeutics Reports Second Quarter 2025 Financial Results
  -- First patient dosed in ELEVATE-44-201 with data from first patient cohort anticipated in H1 2026 -- -- Initiated ELEVATE-45-201 and on track to dose the first patient in Q3 2025 -- -- Multiple clinical trial sites in U.K. and EU activated for ELEVATE-44-201 and ELEVATE-45-201 -- -- Leadership team expanded with the additions of Navid Khan, PhD, as Senior Vice President of Medical Affairs and Kiran Patki, MD, MSc, FFPM, as Senior Vice President of Clinical Development -- -- Cash runway expecte
  Aug 6, 2025 - $TRDA
• Entrada Therapeutics, Inc. (TRDA) Reports Q2 Loss, Lags Revenue Estimates
  Entrada Therapeutics (TRDA) delivered earnings and revenue surprises of -20.93% and -78.02%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
  Aug 6, 2025 - $TRDA
• Entrada Therapeutics (TRDA) Soars 5.6%: Is Further Upside Left in the Stock?
  Entrada Therapeutics (TRDA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
  Jul 31, 2025 - $TRDA
• Entrada Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors
  Maha Radhakrishnan, MD Maha Radhakrishnan, MD BOSTON, June 03, 2025 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced the appointment of Maha Radhakrishnan, M.D., to its Board of Directors. “We are pleased to have Dr. Radhakrishnan join the Board at this time of tremendous clinical momentum at Entrada, led by the continued advancement of our Duchenne muscular dystrophy franchise. Dr. Radhakrishnan’s deep and meaningful experience in global drug development will be inv
  Jun 3, 2025 - $TRDA
• Entrada’s Phase I/II trial of DMD treatment authorised to begin in EU
  The company plans to launch ELEVATE-45-201 in the third quarter of this year.
  May 29, 2025 - $TRDA
• Entrada Therapeutics Receives Authorization in the European Union to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in Patients Living with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping
  – Company on track to begin ELEVATE-45-201 in Q3 2025 – – Follows recently received Medicines and Healthcare Products Regulatory Agency authorization in the United Kingdom for ELEVATE-45-201 – BOSTON, May 28, 2025 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced it has received authorization from the Health Authorities and Ethics Committees of multiple countries under the European Union Clinical Trial Regulation (EU-CTR) to initiate ELEVATE-45-201, a Phase 1/2 multip
  May 28, 2025 - $TRDA
• Analysts Are Upgrading Entrada Therapeutics, Inc. (NASDAQ:TRDA) After Its Latest Results
  Entrada Therapeutics, Inc. ( NASDAQ:TRDA ) just released its quarterly report and things are looking bullish. The...
  May 11, 2025 - $TRDA
• Entrada Therapeutics Reports First Quarter 2025 Financial Results
  – Receives regulatory authorization in the EU for ELEVATE-44-201, a Phase 1/2 MAD clinical study of ENTR-601-44 in patients living with Duchenne muscular dystrophy who are amenable to exon 44 skipping – – Company remains on track to initiate ELEVATE-44-201 and ELEVATE-45-201 in Q2 and Q3 2025, respectively – – Cash runway expected into Q2 2027 with $383 million in cash, cash equivalents and marketable securities as of March 31, 2025 – BOSTON, May 08, 2025 (GLOBE NEWSWIRE) -- Entrada Therapeutics
  May 8, 2025 - $TRDA
• Entrada Therapeutics, Inc. (TRDA) Reports Q1 Loss, Tops Revenue Estimates
  Entrada Therapeutics (TRDA) delivered earnings and revenue surprises of 46.15% and 111.61%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
  May 8, 2025 - $TRDA
• Eton Pharmaceuticals, Inc. (ETON) Earnings Expected to Grow: What to Know Ahead of Q1 Release
  Eton Pharmaceuticals (ETON) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
  May 1, 2025 - $TRDA